Compare AbbVie Inc (ABBV) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Etsy Inc — how do they compare? AbbVie Inc trades at $249.53 (market cap $438.19B), while Etsy Inc trades at $80.12 (market cap $7.38B). The key difference: AbbVie Inc is far larger — about 59.4× Etsy Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Etsy Inc pays none. Which is the better fit depends on your goals.
| ABBV | ETSY | |
|---|---|---|
Market Cap | $438.19B | $7.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $86.47 |
52-Week Low | $197.38 | $44.05 |
Enterprise Value | $502.45B | $9.33B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
ETSY trades at $85.55, up 4.0% over 24 hours, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.98, exceeding expectations, and announced a $2 billion share repurchase program alongside a 12% workforce reduction to boost efficiency. Revenue growth remains stable at $2.9 billion for 2026, though net income margins have moderated from prior years.
Outlook is positive with raised 2026 guidance and AI-driven marketplace improvements, but risks include high debt levels and competitive pressures. Analysts are evenly split between Buy and Hold ratings, with a consensus price target of $85.71, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
